Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Vector Biomed
AddedFeb 15, 2024
UpdatedJun 18, 2026
Vector Biomed

Vector Biomed

Series B

Vector Biomed: Your trusted source for high-quality, safe Lentiviral vectors for gene therapies.

HQ
Gaithersburg, MD, US
Founded
2021
Overview
Compare
Fundraising
Employees
Website

Vector Biomed, a cutting-edge company, focuses on the custom design and GMP manufacturing of Lentiviral vectors, essential for gene therapies such as CAR-T cell and Stem Cell gene therapies. The company's mission is to empower gene medicine cures by providing high-quality, safe, and reliable Lentiviral vectors. Their vision is to facilitate the rapid transition from therapeutic concepts to clinical development, offering optimized-by-design vector solutions that support the commercialization of gene medicines.

Notable figures affiliated with Vector Biomed include experts in gene therapy and biotechnology, though specific names are not provided. The company has gained recognition for its rapid and reliable manufacturing processes, which have significantly impacted the gene therapy market by accelerating the development of life-saving treatments. Vector Biomed's contributions have been pivotal in advancing clinical applications and commercialization of gene therapies, positioning them as a trusted partner in the biopharmaceutical industry.

Vector Biomed - Similar Companies

VintaBio logo

VintaBio

vintabio.com

VectorBuilder logo

VectorBuilder

vectorbuilder.com

iVexSol logo

iVexSol

ivexsol.com

Cellomics Technology logo

Cellomics Technology

cellomicstech.com

PackGene Biotech logo

PackGene Biotech

packgene.com

Twister Biotech logo

Twister Biotech

twisterbiotech.com

Vector Vitale logo

Vector Vitale

vectorvitale.com

64x Bio logo

64x Bio

64xbio.com

Carbon Biosciences logo

Carbon Biosciences

carbonbio.com

ImmunoVec logo

ImmunoVec

immunovec.com

Center for Breakthrough Medicines logo

Center for Breakthrough Medicines

Andelyn Biosciences logo

Andelyn Biosciences

andelynbio.com

ViTToria Biotherapeutics logo

ViTToria Biotherapeutics

vittoriabio.com

ElevateBio logo

ElevateBio

Apertura Gene Therapy logo

Apertura Gene Therapy

aperturagtx.com

Vector Biomed - Quick Facts

Who are Vector Biomed's competitors?

Companies similar to Vector Biomed include VintaBio, VectorBuilder, iVexSol and Cellomics Technology.

When was Vector Biomed founded?

Vector Biomed was founded in 2021.

Where is Vector Biomed's headquarters located?

Vector Biomed's headquarters is located in Gaithersburg, MD, US.

When was Vector Biomed's last funding round?

Vector Biomed's most recent funding round was for $15M (USD) in December 2022.

How much has Vector Biomed raised to-date?

As of Dec 8, 2022, Vector Biomed has raised a total of $15M (USD).

How many employees does Vector Biomed have?

Vector Biomed has 5 employees as of Feb 5, 2024.

Vector Biomed - Classification

Ownership
  • Private
Technology
  • Biotech
Geographic Exposure
  • Global
Model
  • Manufacturing
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Lentiviral Vectors
Tags
  • Biotech
  • Gene Therapy
NAICS
  • 330000Manufacturing
  • 333000Machinery Manufacturing
  • 333100Agriculture, Construction, and Mining Machinery Manufacturing
SIC
  • 3500Industrial And Commercial Machinery And Computer Equipment
Show 1 more industry code
SIC
  • 3900Miscellaneous Manufacturing Industries